Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers
ID: 360387Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360387
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for a cooperative agreement aimed at developing optimal treatment strategies for the use of anti-obesity medications (AOMs) in children and adolescents. This initiative seeks clinical centers to join a consortium focused on testing AOM treatment strategies that maximize benefits while minimizing risks, emphasizing healthy growth, nutritional intake, and mental well-being. The project is critical in addressing obesity in youth, with a focus on determining the best developmental stages for AOM initiation and evaluating predictors of treatment response. Interested applicants can reach out to Dr. Stavroula K. Osganian at (301) 827-6939 or via email at voula.osganian@nih.gov. The estimated award date is July 1, 2027, with applications due by December 1, 2026, and a total of three awards expected.

    Point(s) of Contact
    Stavroula K. Osganian, MD, ScD, MPH
    (301) 827-6939
    voula.osganian@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for a Cooperative Agreement to establish a Research Coordinating Center (RCC) focused on optimal treatment strategies for the use of anti-obesity medications (AOMs) in children and adolescents. The RCC will coordinate a consortium of clinical centers to evaluate various AOM treatment strategies, including the timing of AOM initiation, weight loss rates, medication classes, dosages, and the integration of lifestyle therapies to support healthy development and minimize long-term reliance on AOMs. This initiative is critical for addressing obesity in youth and ensuring effective treatment protocols, with one award expected to be made. Interested applicants can reach out to Dr. Stavroula K. Osganian at (301) 827-6939 or via email at voula.osganian@nih.gov for further details. The estimated project start date is July 1, 2027, with applications due by December 1, 2026.
    Nutrition Obesity Research Centers (NORCs)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Nutrition Obesity Research Centers (NORCs) program, which aims to establish core centers that contribute to an integrated program of nutrition and obesity research. This funding opportunity supports three primary research-related activities: Research Core services, a Pilot and Feasibility program, and an Enrichment program, all designed to enhance the efficiency and multidisciplinary nature of research in this critical health area. With an estimated total program funding of $3.6 million and the expectation of awarding three grants, interested applicants can reach out to Dr. Mary Evans at evansmary@niddk.nih.gov or call 301-594-4578 for further information. The application process is open until October 1, 2026, with awards anticipated to be made by June 1, 2027.
    Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents." This initiative aims to advance research in determining optimal dosing strategies for new psychiatric medications in children and adolescents suffering from serious mental illnesses, focusing on the development of central nervous system (CNS) tools and models to assess medication effects on the brain. The opportunity is particularly relevant for researchers with expertise in pediatric psychiatry, neuroimaging, and clinical pharmacology, as it seeks to improve the safety and effectiveness of pediatric clinical trials through the establishment of pharmacodynamic measures. Interested applicants can reach out to Dr. Margaret C. Grabb at mgrabb@mail.nih.gov or by phone at 301-443-3563 for further information, with the estimated synopsis post date set for December 13, 2025, and the close date anticipated for February 13, 2026.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated, high-risk multi-center clinical trials through the Notice of Funding Opportunity (NOFO) PA-25-147. This cooperative agreement (U01) aims to support innovative studies that address critical health issues related to diabetes, digestive diseases, and kidney conditions, requiring proposals to be hypothesis-driven and operationally classified as high-risk. The program emphasizes the importance of diverse perspectives in research and mandates that planning activities be completed prior to application submission. Interested applicants should note that the application period opens on January 3, 2025, with a submission deadline of November 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is seeking a qualified entity to continue the Physiology of the Weight Reduced State (POWERS) Study through a cooperative agreement. This initiative aims to further investigate the physiological processes that contribute to individual differences in weight regain after weight loss, allowing for the completion of the clinical trial and subsequent data analysis. The POWERS study is critical for understanding obesity and developing effective weight management strategies. Interested applicants should note that the estimated project start date is April 1, 2027, with a single award anticipated, and they can contact Dr. Mary Evans at NIDDKObesity@nih.gov or by phone at 301-594-4578 for further information.
    Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)" aimed at supporting research into effective interventions for substance use disorders (SUDs) and overdose. This cooperative agreement encourages applications for preclinical and clinical studies focusing on pharmacotherapies, device-based treatments, digital therapeutics, and behavioral interventions, with the goal of advancing these interventions towards regulatory approval or clinical adoption. The funding amount can reach up to $3 million, and applications are due by 5:00 PM local time, with multiple submission cycles from October 2025 to August 2028. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support
    National Institutes of Health
    The National Institutes of Health (NIH) is seeking to establish a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through a Cooperative Agreement aimed at enhancing the development of new pharmacotherapeutics for SUD. The Center will focus on educating researchers in formal product development and providing technical and financial support for initial experiments, with an emphasis on creating a product development curriculum and fostering collaborations within the research community. This initiative is crucial for advancing drug addiction research and supporting the translation of innovative concepts into practical applications. The estimated total program funding is $3 million, with one award expected, and interested parties can contact Dr. Tam Nguyen at Tam.Nguyen@nih.gov or (301) 451-1203 for further information. The estimated synopsis post date is November 21, 2025, with applications expected to close on January 27, 2026, and the project anticipated to start on September 1, 2026.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk, multi-center observational studies related to diabetes, digestive, kidney, and associated diseases. This funding opportunity emphasizes hypothesis-driven research that engages diverse populations, particularly underserved communities, and requires a comprehensive study design, community engagement, and a detailed budget. The initiative is crucial for advancing health equity and enhancing participant diversity in clinical research. Interested applicants should note that the submission period opens on January 3, 2025, with a closing date of November 5, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Time-Sensitive Evaluation of Policies Affecting Health Behaviors and Chronic Disease Risk (R01-Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Time-Sensitive Evaluation of Policies Affecting Health Behaviors and Chronic Disease Risk," aimed at supporting research that evaluates policies influencing obesity-related behaviors and chronic disease risk. Applicants must demonstrate that their proposed evaluations represent unique research opportunities that necessitate prompt initiation, particularly focusing on policies affecting diet, physical activity, and weight outcomes in populations vulnerable to health disparities. This initiative reflects NIH's commitment to addressing critical public health issues through scientific evaluation and community-focused approaches, with a maximum project duration of five years and no specific budget limits. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with the application deadline set for January 11, 2028.